Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darrell R Fisher

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Bioconjugate Chemistry|November 14, 2017
Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle RadiationManankumar A Shah, Xiuli Zhang, Raffaella Rossin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapyGeorge Sgouros, John C Roeske, Michael R McDevitt, et al.
Nuclear Medicine Communications|September 8, 2012
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testesNaoya Hattori, Ajay K Gopal, Andrew T Shields, et al.
Blood|June 19, 2002
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow graftsBrenda M Sandmaier, Wolfgang A Bethge, D Scott Wilbur, et al.
Blood|March 1, 2003
Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantationWolfgang A Bethge, D Scott Wilbur, Rainer Storb, et al.
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric ModelsJaline Broqueza, Chandra B Prabaharan, Kevin J H Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate modelEneida R Nemecek, Donald K Hamlin, Darrell R Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Melanoma therapy via peptide-targeted {alpha}-radiationYubin Miao, Mark Hylarides, Darrell R Fisher, et al.
Clinical Nuclear Medicine|May 21, 2019
A Critical Assessment of the Linear No-Threshold Hypothesis: Its Validity and Applicability for Use in Risk Assessment and Radiation ProtectionJeffry A Siegel, Antone L Brooks, Darrell R Fisher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Bioconjugate Chemistry|November 14, 2017
Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using α-Particle RadiationManankumar A Shah, Xiuli Zhang, Raffaella Rossin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 19, 2010
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapyGeorge Sgouros, John C Roeske, Michael R McDevitt, et al.
Nuclear Medicine Communications|September 8, 2012
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testesNaoya Hattori, Ajay K Gopal, Andrew T Shields, et al.
Blood|June 19, 2002
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow graftsBrenda M Sandmaier, Wolfgang A Bethge, D Scott Wilbur, et al.
Blood|March 1, 2003
Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantationWolfgang A Bethge, D Scott Wilbur, Rainer Storb, et al.
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric ModelsJaline Broqueza, Chandra B Prabaharan, Kevin J H Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate modelEneida R Nemecek, Donald K Hamlin, Darrell R Fisher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Melanoma therapy via peptide-targeted {alpha}-radiationYubin Miao, Mark Hylarides, Darrell R Fisher, et al.
Clinical Nuclear Medicine|May 21, 2019
A Critical Assessment of the Linear No-Threshold Hypothesis: Its Validity and Applicability for Use in Risk Assessment and Radiation ProtectionJeffry A Siegel, Antone L Brooks, Darrell R Fisher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.
Pageof 9